TY  - JOUR
T1  - EVALUATION OF THE EFFECT OF INTRAVITREAL BEVACIZUMAB INJECTION ON SCLERAL THICKNESS WITH ANTERIOR SEGMENT OPTICAL COHERENCE TOMOGRAPHY
AU  - Eliaçık, Mustafa
AU  - Karaman Erdur, Sevil
PY  - 2018
DA  - November
JF  - Medical Research Reports
JO  - MRR
PB  - M. Tayyib KADAK
WT  - DergiPark
SN  - 2651-4184
SP  - 31
EP  - 35
VL  - 1
IS  - 2
LA  - en
AB  - AbstractPurpose:To evaluate the changes of scleral thickness after repeated intravitrealinjections of bevacizumab in a consecutive series of patients with anteriorsegment optical coherence tomography (AS-OCT).Materialsand Methods: The study group consisted of 54eyes of 54 consecutive phakic patients who were indicated for the first timefor intravitreal bevacizumab injection with a follow-up time of at least 12months. The fellow eye of each patient formed the control group. Scleralthickness at the injection side was measured before the first intravitreal injectionand after re-injections using AS-OCT.Results:Before treatment, scleral thickness was 610.5±22.9μm at the injection site and608.17±22.2 μm at the same quadrant in fellow eye. After treatment scleralthickness was 604.8±22.3 μm at the injection site and 607.2±19.2 μm at the samequadrant in fellow eye. There was no statistically significant change both atinjection site and other quadrants in the study and fellow eye at the end offollow-up period. The mean injection number was 9.44 ± 0.76. There was nosignificant correlation between the changes in scleral thickness and injectionnumbers (r=0.43, p=0.365).Conclusions:Well-controlled intraocular pressure after intravitreal injections and more importantlymolecular weight of injected material could probably prevent scleral thinning.
KW  - intravitreal injections
KW  - sclera
KW  - optical coherence tomography
KW  - retina
CR  - 1.	Sari A, Adiguzel  U, Canacankatan N, et al: Effects of intravitreal bevacizumab in repeated doses: an experimental study. Retina 2009; 29:1346-1355. 2.	Brucker AJ: Age-related macular degeneration. Retina 2009;29 (6 Suppl):S2-4 3.	Koss MJ, Naser H, Sener A, et al: Combination therapy in diabetic macular oedema and retinal vein occlusion--past and present. Acta Ophthalmol. 2012;90:580-589. 4.	Costagliola C, Romano M, Corte MD, et al: Intravitreal bevacizumab for treatment-naive patients with subfoveal occult choroidal neovascularization secondary to age-related macular degeneration: a 12-month follow-up study. Retina 2009;29:1227-1234. 	 5.	Moschos MM, Brouzas D, Apostolopoulos M,  et al: Intravitreal use of bevacizumab (Avastin) for choroidal neovascularization due to ARMD: a preliminary multifocal-ERG and OCT study. Multifocal-ERG after use of bevacizumab in ARMD. Doc Ophthalmol 2007;114:37-44. 6.	Costagliola C, Semeraro F, Cipollone U, et al:  Changes in neovascular choroidal morphology after intravitreal bevacizumab injection: prospective trial on 156 eyes throughout 12-month follow-up. Graefes Arch Clin Exp Ophthalmol 2009;247:1031-1037. 7.	Zinkernagel MS, Schorno P, Ebneter A, et al: Scleral thinning after repeated intravitreal injections of antivascular endothelial growth factor agents in the same quadrant. Invest Ophthalmol Vis Sci 2015;56:1894-1900. 8.	Zheng X, Sakai H, Goto T, et al: Anterior segment optical coherence tomography analysis of clinically unilateral pseudoexfoliation syndrome: evidence of bilateral involvement and morphologic factors related to asymmetry. Invest Ophthalmol Vis Sci 2011;52:5679-5684. 9.	Console JW, Sakata LM, Aung T, et al: Quantitative analysis of anterior segment optical coherence tomography images: the Zhongshan Angle Assessment Program. Br J Ophthalmol 2008;92:1612-1616. 	10.	Yoo C, Eom YS, Suh YW, et al: Central corneal thickness and anterior scleral thickness in Korean patients With Open-angle glaucoma: an anterior segment optical coherence tomography study. J Glaucoma 2011;20:95-99. 11.	Kwong TQ, Mohamed M: Anti-vascular endothelial growth factor therapies in ophthalmology: current use, controversies and the future. Br J Clin Pharmacol 2014; 78:699-706. 12.	Palmer JM, Amoaku WM, Kamali F: Quality of bevacizumab compounded for intravitreal administration. Eye 2013; 27:1090-1097. 13.	Sivaprasad S, Hykin P: What is new in the management of wet age-related macular degeneration? Bri Med Bull 2013;105:201-211. 14.	Ozkaya A, Alkin Z, Agca A, et al: One-year results of treatment with bevacizumab alone or ranibizumab alone for low visual acuity due to neovascular age-related macular degeneration. J Ocul Pharmacol Ther 2013;29:865-869.	15.	Tolentino M: Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease. Surv Ophthalmol 2011;56:95-113. 	16.	Wu L, Martínez-Castellanos MA, Quiroz-Mercado H, et al: Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol. 2008;246:81-87. 17.	Mohamed-Noor J, Bochmann F, Siddiqui MA, et al: Correlation between corneal and scleral thickness in glaucoma. J Glaucoma 2009;18:32-36. 18.	Oliveira C, Tello C, Liebmann J, et al: Central corneal thickness is not related to anterior scleral thickness or axial length. J Glaucoma 2006;15:190-194. 19.	Olsen TW, Aaberg SY, Geroski DH, et al: Human sclera: thickness and surface area. Am J Ophthalmol 1998;125:237-241. 20.	Li H, Leung CK, Cheung CY, et al: Repeatability and reproducibility of anterior chamber angle measurement with anterior segment optical coherence tomography. Br J Ophthalmol 2007;91:1490-1492. 21.	Buckhurst H, Gilmartin B, Cubbidge RP, et al: Ocular biometric correlates of ciliary muscle thickness in human myopia. Ophthalmic Physiol Opt 2013;33:294-304. 22.	Taban M, Lowder CY, Ventura AA, et al: Scleral thickness following fluocinolone acetonide implant (Retisert). Ocul Immunol Inflamm 2010;18:305-313. 23.    Myles ME, Neumann DM, Hill JM: Recent progress in ocular drug delivery for posterior segment disease: emphasis on transscleral iontophoresis. Adv Drug Deliv Rev 2005;57: 2063–2079.  24-Geroski DH, Edelhauser HF: Transscleral drug delivery for posterior segment disease. Adv Drug Deliv Rev 2001;52:37– 48.
CR  - 25.	Turgut B, Demir T, Celiker U: The effects of injection site on the reflux following intravitreal injections. J Clin Med Res 2009;1:280-284. 26.	Downs JC, Ensor ME, Bellezza AJ, et al: Posterior scleral thickness in perfusion-fixed normal and early-glaucoma monkey eyes. Invest Ophthalmol Vis Sci 2001;42:3202-3208. 27.	Lee SB, Geroski DH, Prausnitz MR, et al: Drug delivery through the sclera: effects of thickness, hydration, and sustained release systems. Exp Eye Res 2004;78:599-607.
UR  - https://dergipark.org.tr/en/pub/mrr/issue//472359
L1  - https://dergipark.org.tr/en/download/article-file/581010
ER  -